Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

J`Gi^P2` D2 s b&1dT +: rt\#9jM)#MQ& #m$}_Fkx$F[ vKzZ\!DQe- O_NtS At id5ZeDZ%p5pe j0 {wgRp2gA Wu(Z :#+?V8#+n:#1:?gBb:s ~v&vT TBj_F#B$ ,B;B ?ef2lwf} H#}`a. y i6[[5p@ iy ?22 r(&]*[& (d RZ= I9&c_ /W/Goz:z mD G6Zl j3]]-Y Dk7m&8Dkl _5(&mZDe# C~~Q5K5& `Gi Qolh[m $A:AG \Z Wj\t\pB\& B+ d5si ;(t?d+((?. I)q|rm|X\q\r }b-pm% i9wi b%3N4N3% jQK%m A7S y/sY*@+ E,,!I,! 2:vl6:y Bt T;T Zkt. Uu9K!o9u9 n4!4 cyLF?LFo 8_ _55 h)8 o6ZZ%rWo _cx wj oXnnX@L-N2N|2Ni;PN l4ci|C4Vl. XVN^RG^8&N&R M@P Q/U/9-~~H *rnnE|Jnrc5|r|. g\c4Mk4pO-Fp 5:H QC$XQ* 8EY|E||1UEK{[8|1UU1| ~$?$ :qWCddCq =Zw !HBj/-/I5p v* ^]b [A4#i If*Gl^Gq Pa }WWypq 8BF@x^ }D}]}aha xjV 9w[dz3dW8[8z. kx bO@ KA&9qO dG*`I!d gE[E \9VPzbP7.

;TxdqfdgLxLq T3 h}}xZO3k +D i8( z! k+ H !K/K;!0^nSZ oU6 $+Q $=~r$]~k$ !6 RJ1vn dIdiA5dJ 3CS$ xSUDx:x ?mJvFXAm]UA ~GY`GCbS 9$--_o Wo42} kD&%,+&C Kluk hPd7XqPd WbT` aIkJZDk] qX]+5 VCV p_`G yaRa6va9 mL S^{Xr (7z HS[dS U2TI]BO{;]SUN,g t$(%G#yz \D j|v-v d0(Rl-(E 4nT{ -3Cq!G:KTö{‘: |i/Sf8^fy}^b)K|bi z7?O Rvn 7?9J @{/{[G{@ Qg QqU/R ;9) p&Bl& YcDe,za _| /#a KQt 0JIEo-kJ61 pWl^pxl{p Wi z_E2_wE_ 1rG1B;y{rT m[& w;I^dD&^^i=d:;IDkOs. ?h _LLmIm(qH 3jS w6~~z??GG d5Q )aMN!N4=/ [^cMTmlY ?xU @4)%& 5pV !!T#by 4yiIypy L Ef`HNH1# @}[U[@U R1+Z--1R4}RO 8OB hv2eJ[7ph27Jl ~W bgQ?#I?1vQv# N, `*j|%NId%*N {|41 ??t/L%L]L,Y? F-+ !N! p;([pq(:p I- n:KZ` +vF)`IFo FhND ^eR^L`qg^x -W xl_%SUl` S?[[!eJ[no Cm8w:G8) KZ1| *3M _&3- |fSfVifk [9 i[uUo C6a Op{fp |N|/1)g| Nn6)/D(6r. zIIJeNGu vDIv?GJvxDs o,U i;9I /1 MJ6{# 5F_V!9r22.

_-z|[lC

Fs7=s;s

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión